FDA Accepts Supplement for Fenofibrate by Bostal
The FDA has accepted a supplemental application (ANDA208476) for fenofibrate submitted by Bostal.
Asset / Drug
Drug and asset intelligence for Bostal with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.